). The median b2-microglobulin was 2.5 (0-9.3); marrow karyotypes were normal in 88%. The phase I dose-limiting toxicity was Xgrade 2 pulmonary toxicity 2 months post-SCT. Other endpoints were response rate and progression-free survival (PFS). HDM was safely escalated to 200 mg/m 2 ; treatment-related mortality was 2% and Xgrade 2 pulmonary toxicity 10%. The complete (CR) and near complete (nCR) response rate was 49%. With a median post-SCT followup of 2.9 years, the PFS and overall survival (OS) post-SCT were 2.3 and 4.7 years. PFS for those with CR or nCR was 3.1 years while for those with stable disease (SD) it was 1.3 years (P ¼ 0.06). We conclude that carmustine can be combined with HDM for myeloma with minimal pulmonary toxicity and a high response rate.
Introduction
It is likely that the median survival of patients with multiple myeloma treated in 2005 exceeds 5 years. The disease, however, remains incurable and, despite improved survival, the burden of disease-related complications and the side effects of long-term treatment with steroids and newer agents such as thalidomide and bortezomib are significant. For most patients under 65, dose-intensive melphalan in single or tandem stem cell transplant (SCT) early in the course of disease remains the most effective single therapy. [1] [2] [3] Furthermore, despite the time required to undergo and recover from SCT, usually 3-6 months, the period of quiescent disease post-SCT allows many patients to regain a near normal quality of life without cytotoxic medications for years. 4 Autologous SCT for myeloma is generally not curative. Evidence from phase III trials, however, has shown a survival advantage of 1-2 years with SCT versus continuous alkylatorbased therapy.
2,3 CR rates of 30-40% and median posttransplant survivals of 4-5 years have been documented in numerous phase II and III SCT trials, with the biology of the disease greatly influencing OS. [5] [6] [7] Patients with t (11;14) or with low b2-microglobulin and without abnormalities of chromosome 13 appear to achieve the greatest benefit with respect to durability of response and OS post-SCT. [8] [9] [10] In phase III trials, melphalan 200 mg/m 2 has been compared to conditioning regimens that utilize total body irradiation and has been shown to be equally effective and less toxic. 11, 12 In addition, studies comparing cohorts of patients treated with melphalan alone or with combinations including busulfan, cyclophosphamide and other agents have not convincingly demonstrated a benefit for alternative conditioning regimens. 13 In studies in which melphalan is combined with other alkylating agents, the dose of melphalan has often been fixed at less than 200 mg/m 2 and a phase I dose-finding schema has not been employed. 14 We report a phase I/II trial in which intravenous carmustine (bischloroethylnitrosourea or BCNU, 300 mg/m 2 on day À4), an alkylating agent with activity against myeloma, was combined with escalating doses of intravenous melphalan for myeloma patients undergoing SCT. Carmustine can cause pulmonary toxicity, usually in the form of interstitial pneumonitis, possibly due to the inhibition of glutathione reductase in alveolar macrophages; melphalan can have pulmonary toxicity as well. [15] [16] [17] The dose-escalation schema and trial design were linked with serial assessments of pulmonary function. 18, 19 We report minimal pulmonary toxicity at the highest planned dose level (melphalan 200 mg/m 2 ) with a 49% rate of complete and near complete responses (CR).
Patients and methods
Patients 18-71 years of age were eligible for this phase I/II Institutional Review Board (IRB)-approved trial provided that they had multiple myeloma, had received prior therapy but not stem cell transplant (SCT), and had no significant comorbid disease precluding SCT. Eligibility requirements included creatinine clearance 450 ml/min, total bilirubin o1.5 mg/dl, left ventricular ejection fraction 450%, and pulmonary diffusing capacity 450% predicted. Pulmonary function studies were performed in the same laboratory at our center and included flow volumes, diffusing capacity adjusted for hemoglobin, and oxygen saturation before and after exercise. Pulmonary function studies were reported by pulmonary physicians.
Initial diagnostic and staging evaluations, baseline cytogenetics and florescent in situ hybridization (FISH), initial therapies and myeloma status at enrollment were documented for all patients. All patients provided written informed consent and had peripheral blood stem cell (PBSC) products containing at least two million CD34 þ cells/kg cryopreserved prior to enrollment. Patients received carmustine 300 mg/m 2 on day À4 and, in the phase I portion of the trial, intravenous melphalan at 80, 90 or 100 mg/m 2 /day on days À3 and À2. PBSC were infused on day 0 and patients received standard supportive-care measures as previously described. [20] [21] [22] Toxicities were scored using National Cancer Institute clinical toxicity criteria. 23 No maintenance therapy was employed.
The primary endpoints of the trial were safety (i.e., frequency of Xgrade 2 pulmonary toxicity, defined as a decrease in diffusing capacity to 50-75% of baseline) and myeloma response rate and durability. A Simon two-stage trial design was employed with grade 2 pulmonary toxicity on day þ 60 (confirmed on day þ 90) as the phase I dose-limiting toxicity.
The maximum tolerated dose of melphalan was defined as the highest dose for which the incidence of dose-limiting toxicity was less than 33%. In addition, if six patients exhibited confirmed Xgrade 2 pulmonary toxicity during the study, the trial would close.
Myeloma testing included b2 microglobulin, albumin, serum and urine electrophoresis and immunofixation, and radiographic studies (skeletal survey, total spine MRI). Patients were staged prospectively by the Durie-Salmon staging system at the time initial therapy was given and retrospectively by the International Staging System (ISS). 24, 25 The latter employs baseline serum albumin and b2 microglobulin; patients with b2 microglobulin 45.5 mg/dl are stage 3, while those with albumin 43.5 g/dl and beta 2o3.5 are stage 1, and those who are neither 1 nor 3 are stage 2.
Myeloma response and relapse definitions were based on EORTC consensus criteria (Blade criteria). 26 Responses were scored separately after initial therapy and mobilization and after SCT. CR requires immunofixation showing no evidence of the prior M protein, a normal bone marrow exam, and no radiographic evidence of myeloma progression. Near complete response (nCR) requires a 490% reduction in the M protein with persistent evidence of disease on immunofixation. Partial response (PR) requires a 450% reduction in M protein and stable radiographic studies. Stable disease is defined as no change in M protein, while progression of disease is defined as recurrence of disease after CR or a 425% increase in M protein from nadir. Bone marrow studies were needed to confirm CR.
After transplant, all patients had pulmonary function testing with diffusing capacity performed at 2 and 12 months. If grade 2 pulmonary toxicity was indicated at 2 months, then confirmatory testing was performed 1 month later. All patients were evaluated for myeloma status at 3, 6 and 12 months post-SCT and quarterly thereafter, and were followed until death.
Statistics
All statistical analyses were performed with PRISM (GraphPad, San Diego, CA, USA). In the analysis of PFS and OS, correlation with best response post-SCT was assessed with a landmark analysis including only patients who survived 100 days post-SCT. Also, patients undergoing reduced-intensity allogeneic stem cell transplant (RIAT) were censored at the time of RIAT. Kaplan-Meier analysis was used to depict survivals with comparisons made by log-rank test, and univariate analyses were performed by log-rank also. Comparisons were two-tailed unless otherwise specified, using Po0.05 significance level.
Results

Patients
Patients were enrolled and treated on this protocol from 2/1/ 1999 to 11/1/2003, 12 on the phase I and 37 on the phase II portion. Patient characteristics and Durie-Salmon and ISS stages at diagnosis are shown in Table 1 . As initial therapies patients received melphalan and prednisone (n ¼ 2), dexamethasone (n ¼ 13), VAD (vincristine, adriamycin and D, n ¼ 13), TAD or TD (thalidomide, A and D, n ¼ 14), C-VAMP (cyclophosphamide, V, A and methylprednisolone, n ¼ 6) and Gentasense and dexamethasone (n ¼ 1). Eight patients received two initial regimens.
For further therapy and for stem cell mobilization, 19 patients received melphalan 60 mg/m 2 and G-CSF, as previously described, and 28 received cyclophosphamide 3000 mg/m 2 and G-CSF (one cycle ¼ 20, two cycles ¼ 2, three cycles ¼ 6). 22 Two patients were mobilized with G-CSF alone. Responses after initial therapy and mobilization are shown in Table 2 by DurieSalmon stage; responses by ISS stage were similar except that none of the ISS stage three patients achieved CR or nCR. Table 2 Responses to initial therapy and mobilization prior to stem cell transplant (n ¼ 49) 
Stem cells and engraftment
Patients received a median of 5.6 Â 10 6 CD34 þ cells/kg (range, 2.3-11.4). The CD34 þ cell dose at transplant for each patient was selected by the treating physician and represented a fraction of the total CD34 þ cells collected. For all patients, neutrophils (absolute neutrophil count 4500 for 3 days) and platelets (450 000/ml without transfusion) recovered in medians of 9 (7-10) and 14 (10-26) days, respectively.
Toxicities
There was one treatment-related death in phase II due to sepsis associated with the transfusion of bacterially contaminated platelets that resulted in multi-organ failure. Therefore, 100 day treatment-related mortality, was 2% (1/49). Overall, one patient had grade 4 pulmonary toxicity with grade 3 hypoxia and four had asymptomatic grade 2 pulmonary toxicity at 3 months post-SCT without hypoxia. Of 16 patients with baseline diffusing capacity from 50 to 70% predicted, one developed grade 4 pulmonary toxicity, while of 30 patients with diffusing capacity 471% at baseline, four developed grade 2 toxicity. Changes in diffusing capacity with time are shown in Figure 1a . Although there was a minimal decrement in diffusing capacity at 2 months post-SCT in the majority of patients, by 12 months post-SCT there was recovery and overall improvement.
The patient with grade 4 pulmonary toxicity also had perforation of the colon on day 0 requiring partial colectomy with colostomy. He then developed biopsy-proven bronchiolitis obliterans organizing pneumonia (BOOP) within 100 days of SCT, possibly related to oxygen exposure perioperatively immediately after dose-intensive carmustine and melphalan. He was treated with tapering doses of steroids and made a complete recovery. There were no other unexpected grade 3 or 4 toxicities.
Myeloma responses
The distribution of disease responses post-SCT is depicted in Figure 1b . In all, 49% of patients (24/ 
Progression-free and overall survivals
At the time of reporting (2/1/05), median follow-up post-SCT is 2.9 years (0.11-5.9). The median time from diagnosis to SCT was 0.67 years (range, 0.33-8.3). PFS and OS post-SCT are depicted in Figure 2 with median survivals shown with inset lines. The median PFS and OS post-SCT were 2.3 and 4.7 years.
PFS and OS post-SCT were evaluated as a function of age, gender, cytogenetic karyotype, Durie-Salmon and ISS stage, initial therapy, type of mobilization, time from diagnosis to SCT, CD34 þ cell dose at SCT and best response post-SCT. None of these variables, except CD34 þ cell dose, was significantly correlated with PFS or OS. Patients achieving CR or nCR had a median PFS of 3.1 years while those with PR and SD had medians of 1.8 and 1.3 years, respectively. In the comparison of CR/nCR with SD, the difference in post-SCT PFS approached significance (P ¼ 0.06). OS was not significantly better in those who achieved CR or nCR post-SCT compared to those with SD. OS was significantly worse in those who had CD34 þ cell doses of 2-4 Â 10 6 /kg compared to those who had doses 48 Â 10 6 /kg (P ¼ 0.049, median OS 4.6 years vs not reached). The 11 patients who received CD34 þ cell doses of 2-4 Â 10 6 /kg had fewer stem cells collected than the others (data not shown) but had post-SCT responses typical of the larger group (CR ¼ 4, PR ¼ 6, SD ¼ 1).
Discussion
In this report, we describe a phase I/II clinical trial of autologous stem cell transplantation using a carmustine and melphalan conditioning regimen in patients with multiple myeloma. Careful evaluation of organ-specific toxicity is required in the development of new autologous transplant conditioning regimens, particularly when autologous SCT is palliative and not curative. 27 A central concern of this trial was whether combining carmustine and melphalan in high doses would increase the frequency and severity of pulmonary toxicity. Our results demonstrate that pulmonary toxicity with this regimen is minimal. Patients on this study had pulmonary function testing performed at baseline, and 2 and 12 months post-SCT, with confirmatory testing at 3 months if pulmonary toxicity was indicated. The incidence of grade 2-4 pulmonary toxicity was 10% (5/49) and, with the exception of one patient with BOOP, all were asymptomatic. The decrement in diffusing capacity at 2 months post-SCT was statistically significant but not clinically relevant. The improvement noted at 12 months further supports the conclusion that pulmonary toxicity was minimal.
Half of all patients achieved CR or nCR with low treatmentrelated mortality. The responses were durable; those achieving CR had PFS of over 3 years. Of note, however, is the profile of the patients enrolled on this study. Only 12% had abnormal karyotypes at diagnosis and only a small fraction had 13q abnormalities by FISH. Nevertheless, nearly half of the patients were ISS stage 2 and 3, indicating that many had elevated b2 microglobulin levels, and all were symptomatic with DurieSalmon stage II and III myeloma. The survival observed post-SCT likely reflects the cytogenetic profile. It is less clear how higher CD34 þ cell doses at SCT may provide a benefit with respect to OS. It is possible that higher CD34 þ cell doses reflect overall disease burden since the subset of patients rescued with 2-4 Â 10 6 CD34 þ cells/kg had fewer CD34 þ cells collected; alternatively, higher CD34 þ cell doses may be associated with an increased number of infused lymphocytes and may lead to more robust immunologic recovery. 28 Our results suggest that disease response may impact progression-free survival. The biology of the disease likely plays a role here. For patients with normal cytogenetics and FISH, achievement of CR and nCR may contribute to extended survival; for those with abnormal cytogenetics, therapies that make the disease more indolent may provide greater benefit. The search for such therapies remains critical to patients with myeloma; the apparent effectiveness of bortezomib in patients with and without 13q abnormalities is both a case in point and a sign of hope for this on-going effort. 29 Attempts to enhance the efficacy of high-dose melphalan in SCT for multiple myeloma include an increase in the dose of melphalan with or without a mucosal protectant, the use of multiple alkylator therapy, and the addition of a radiopharmaceutical to melphalan. [30] [31] [32] [33] Preliminary data from these attempts, as well as from this trial, suggest that despite such efforts efficacy may not be significantly enhanced with a single SCT. The use of novel combination therapies in tandem SCT or after an initial SCT with standard melphalan dosing remains to be explored in this regard.
Finally, it is worth noting that, in an evaluation of high-dose melphalan dose schedules, the incidence of Xgrade 2 pulmonary toxicity in patients receiving melphalan 200 mg/m 2 in 1 dose on 1 day was 14%; dividing the drugs on this trial over 3 days as we did likely contributes to the tolerance of the regimen and the minimal toxicity observed. 34 It is also worth noting that the use of diffusing capacity 450% predicted as a criterion of acceptability for autologous stem cell transplant was adopted from allogeneic bone marrow transplant. Its use may be in need of revision in the era of mobilized peripheral blood stem cells with respect to autologous transplant patients with no prior irradiation to the chest or mediastinum who are not receiving conditioning regimens containing total body irradiation. 35 Is the combination of carmustine and melphalan worth developing further for myeloma transplant? The CR rate of 41% with this single SCT is similar to that achieved with tandem transplant using melphalan 200 mg/m 2 . 1 Whether this combination would be feasible in a tandem transplant may be worth exploring based on the results of this trial. The addition of a novel third agent to this combination is also a possibility. Such an agent ideally would have a dose-response in myeloma and a unique mechanism of action (i.e., it would not be another alkylating agent); and myelosuppression would be its doselimiting toxicity. 
